Diseases & Conditions Market Research Reports & Industry Analysis
Insomnia is a common condition in which one has trouble going to sleep or staying asleep. This condition can range from weak to strong, depending on how often it occurs and for how long. Insomnia can be ongoing or acute. Chronic insomnia means having symptoms at least 3 nights a week for more than a month. Acute insomnia lasts for less time. Some people who have insomnia will have trouble falling asleep. Other people may fall asleep easily but, then wake up.
Diseases & Conditions Industry Research & Market Reports
-
Hyaluronic Acid
... CAGR of 8.1% over the analysis period 2024-2030. Offline, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$1.6 Billion by the end of the analysis period. ... Read More
-
Neglected Tropical Diseases Diagnosis
... 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Conventional, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$5.4 Billion by the end ... Read More
-
Gout Therapeutics
... CAGR of 13.4% over the analysis period 2024-2030. NSAIDs, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$4.7 Billion by the end of the analysis period. ... Read More
-
Autoimmune Disease Therapeutics
... at a CAGR of 3.8% over the analysis period 2024-2030. Anti-inflammatory, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$183.0 Billion by the end of the ... Read More
-
Glucose Monitoring Devices
... at a CAGR of 4.6% over the analysis period 2024-2030. Self-Monitoring Devices, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$11.3 Billion by the end of ... Read More
-
Allergy Treatment
... CAGR of 3.7% over the analysis period 2024-2030. Asthma, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$5.9 Billion by the end of the analysis period. ... Read More
-
Chronic Obstructive Pulmonary Disease (COPD) Treatment
... reach US$27.8 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Combination, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$15.9 ... Read More
-
Tuberculosis Therapeutics
... CAGR of 2.7% over the analysis period 2024-2030. Active TB, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$654.3 Million by the end of the analysis ... Read More
-
Anxiety Disorder Treatment
... at a CAGR of 2.4% over the analysis period 2024-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$4.9 Billion by the end of the ... Read More
-
Hepatitis Therapeutics
... CAGR of 3.7% over the analysis period 2024-2030. Hepatitis C, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$17.8 Billion by the end of the analysis ... Read More
-
Human Insulin
... CAGR of 6.8% over the analysis period 2024-2030. HI Drugs, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$70.6 Billion by the end of the analysis ... Read More
-
Intraoperative Radiation Therapy
... at a CAGR of 6.0% over the analysis period 2024-2030. Systems / Accelerators, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$22.9 Million by the end ... Read More
-
Liver Cancer Diagnostics
... at a CAGR of 7.4% over the analysis period 2024-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$9.8 Billion by the end of ... Read More
-
Non-Invasive Prenatal Testing (NIPT)
... 2030, growing at a CAGR of 10.9% over the analysis period 2024-2030. Consumables & Reagents, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$5.5 Billion by ... Read More
-
Pesticide Inert Ingredients
... at a CAGR of 6.2% over the analysis period 2024-2030. Emulsifiers, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$3.3 Billion by the end of the ... Read More
-
Rare Hemophilia Factors
... at a CAGR of 5.6% over the analysis period 2024-2030. Fresh Frozen Plasma, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$246.9 Million by the end ... Read More
-
Gaucher disease Type 1 - Pipeline Insight, 2025
... and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Gaucher ... Read More
-
Fabry Disease Treatment
... at a CAGR of 8.2% over the analysis period 2024-2030. Enzyme Replacement Therapy, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$1.7 Billion by the end ... Read More
-
2025 Global Gaucher Disease Treatment Market Industry (2031 Outlook)
... for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for 46 countries. The report also features written analysis on market definitions, market segments, market trends, technology ... Read More
-
Gaucher's disease - Pipeline Insight, 2025
... It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Gaucher’s Disease Understanding Gaucher’s Disease: ... Read More
-
Anaplastic lymphoma kinase inhibitors - Pipeline Insight, 2025
... including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global ... Read More
-
Ebola Fever - Pipeline Insight, 2025
... It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Ebola Fever: Understanding Ebola Fever: ... Read More
-
Advanced Melanoma - Pipeline Insight, 2025
... It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Advanced Melanoma: Understanding Advanced Melanoma: ... Read More
-
Ocular Hypertension - Pipeline Insight, 2025
... It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Ocular Hypertension: Understanding Ocular Hypertension: ... Read More
-
2025 Global Gaucher Disease Drugs Market Industry (2031 Outlook)
... for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for 46 countries. The report also features written analysis on market definitions, market segments, market trends, technology ... Read More
Research Assistance
